Back
Blueprint Medicines Stock Price Chart
Big exits started like this. So did Mode
Disclosure: This offer is only open to accredited investors. Please read the offering circular and related risks at invest.modemobile.com/elite
Sell
45
BPMC
Blueprint Medicines
Last Price:
$127.72
Seasonality Move:
8.97%
7 Day Trial
ALL ACCESS PASS
$
7
From 50,000 investors to Nasdaq? Mode's next move...
Disclosure: This offer is only open to accredited investors. Please read the offering circular and related risks at invest.modemobile.com/elite-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing slight selling pressure.
Blueprint Medicines Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 100.77 | Buy |
| 20-day SMA: | 100.36 | Buy |
| 50-day SMA: | 92.03 | Buy |
| 200-day SMA: | 93.53 | Buy |
| 8-day EMA: | 100.48 | Buy |
| 20-day EMA: | 98.66 | Buy |
| 50-day EMA: | 95.34 | Buy |
| 200-day EMA: | 93.7 | Buy |
Blueprint Medicines Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 2.43 | Buy |
| Relative Strength Index (14 RSI): | 56.35 | Buy |
| Chaikin Money Flow: | -361323 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (93.69 - 103.15) | Buy |
| Bollinger Bands (100): | (85.95 - 105.09) | Buy |
Blueprint Medicines Technical Analysis
| May 16 | May 19 | May 20 | May 21 | May 22 | May 23 | May 27 | May 28 | May 29 | May 30 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 16 | 19 | 20 | 21 | 22 | 23 | 27 | 28 | 29 | 30 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 101.35 while BPMC 8-day simple moving average is 100.77, which is a Buy signal.
-
The stock price of BPMC is 101.35 while Blueprint Medicines 20-day SMA is 100.36, which makes it a Buy.
-
Blueprint Medicines 50-day simple moving average is 92.03 while BPMC share price is 101.35, making it a Buy technically.
-
BPMC stock price is 101.35 and Blueprint Medicines 200-day simple moving average is 93.53, creating a Buy signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
45
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $101.35. The Score for BPMC is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
6.5B
Price in USD:
101.35
Share Volume:
903.3K
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
73.04
Sell
45
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 101.35 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 101.35 while BPMC 8-day exponential moving average is 100.48, which is a Buy signal.
-
The stock price of BPMC is 101.35 while Blueprint Medicines 20-day EMA is 98.66, which makes it a Buy.
-
Blueprint Medicines 50-day exponential moving average is 95.34 while BPMC share price is 101.35, making it a Buy technically.
-
BPMC stock price is 101.35 and Blueprint Medicines 200-day simple moving average is 93.70, creating a Buy signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.67 per share, an increase next quarter of $0.33 per share, an increase this year of $0.60 per share, and an increase next year of $1.46 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is 2.43, suggesting Blueprint Medicines is a Buy
-
Blueprint Medicines Relative Strength Index (RSI) is 56.35, which suggest Blueprint Medicines is overbought
-
The Bollinger Bands (25) for Blueprint Medicines is (93.69 - 103.15), which suggest Blueprint Medicines is a Buy
-
The Bollinger Bands (100) for Blueprint Medicines is (85.95 - 105.09), which suggest Blueprint Medicines is a Buy
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.